search
Back to results

Fiber Food Introduction in Pediatric Short Bowel Syndrome

Primary Purpose

Short Gut Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Green bean puree
Sponsored by
Children's Hospital of Philadelphia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Short Gut Syndrome

Eligibility Criteria

4 Months - 18 Years (Child, Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Actively follows at CHOP outpatient clinics
  • SBS arm specific: History of SBS diagnosis. History of short bowel syndrome based on surgical/imaging records. Has ileocecal resection (No ICV) and small bowel is in continuity with some portion of colon
  • Control arm specific: No history of intestinal pathologies
  • No or negligible amount (few bites of fiber-containing foods okay) of fiber in tube feeds or by mouth at baseline
  • Less than 20% calories from oral food not containing fiber while the other 80% may be by enteral and/or parenteral feedings
  • At least 20% calories from fiber-free formula taken orally or via tube
  • Antibiotic use is allowed, however, should be on a stable regimen of antibiotics starting from 2 weeks prior to intervention until end of study or end of week 3 whichever is sooner
  • Previous history of fiber introduction failure is acceptable as long as clinically stable at the time of recruitment
  • Fiber supplementation is appropriate per primary physician

Exclusion Criteria:

  • SBS Arm specific: No diagnosis of SBS. No history of ICV resection.
  • Control Arm specific: has baseline intestinal diseases
  • Small bowel and colon not in continuity (Ex: presence of ileostomy or jejunostomy)
  • >5% changes in percentage of calories from PO, EN and/or PN during the intervention
  • Addition/discontinuation/significant alteration to antibiotics regimen during study period
  • Primary physician does not think fiber supplementation is appropriate clinically

Sites / Locations

  • Children's Hospital of PhiladelphiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Short Bowel Syndrome Arm

Control Arm -

Arm Description

Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.

Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.

Outcomes

Primary Outcome Measures

Symptoms
To assess the rate of continuation and symptoms/signs leading to discontinuation of fiber addition in SBS vs controls

Secondary Outcome Measures

Microbiome/Metabolome Changes
To correlate changes in clinical status on fiber to microbiome/metabolome changes in SBS vs controls

Full Information

First Posted
June 21, 2022
Last Updated
May 5, 2023
Sponsor
Children's Hospital of Philadelphia
Collaborators
University of Pennsylvania
search

1. Study Identification

Unique Protocol Identification Number
NCT05432648
Brief Title
Fiber Food Introduction in Pediatric Short Bowel Syndrome
Official Title
Clinical Tolerance and Microbiome Changes Following Fiber Food Introduction in Short Bowel Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 8, 2022 (Actual)
Primary Completion Date
May 2024 (Anticipated)
Study Completion Date
May 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital of Philadelphia
Collaborators
University of Pennsylvania

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.
Detailed Description
Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support. The goal of SBS treatment is to achieve enteral autonomy using strategies that optimize intestinal absorption while minimizing unpleasant gastrointestinal (GI) side effects. One strategy that has emerged is the addition of soluble fiber to enteral formula, and this strategy has gained popularity in clinical practice as fiber-rich formulas comprised of blenderized whole foods have become commercially available. However, the investigators' preliminary observations suggest that patients with SBS have variable tolerance and growth outcomes on these blenderized feeds. To date, there are no clinical studies documenting the effects of dietary fiber in SBS patients and guidance in enteral nutrition advancement is lacking in this medically complex population. The current study aims to explore the tolerance of controlled fiber addition to enteral formula based on assessment of GI symptoms, and corresponding changes in microbiome composition, and metabolomics in pediatric patients with SBS versus non-SBS controls. The investigators will use a practical approach with fiber introduction and slowly advance to goal fiber intake to understand the factors leading to continuation. Stool, urine, and plasma samples collected pre- and post- intervention will help identify biomarkers that would predict successful fiber tolerance and optimize selection of patients for fiber introduction. While there is no intent to treat, mitigate, prevent, diagnose or cure the symptoms of SBS, the study may help shed light on the underlying mechanism for intolerance to dietary fiber.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Short Gut Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Short Bowel Syndrome Arm
Arm Type
Experimental
Arm Description
Patients with SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
Arm Title
Control Arm -
Arm Type
Active Comparator
Arm Description
Patients without SBS will be initiated on green bean purees added to enteral formula recipes, based on kilocalories of enteral formula over 3 weeks. During week 1 subjects will prepare and add 50 mL green bean puree per 1000kcal of enteral feed (5%) to their formula mixture, increasing to 100ml (10%) and 150ml (15%) during weeks 2 and 3, respectively.
Intervention Type
Dietary Supplement
Intervention Name(s)
Green bean puree
Intervention Description
Green bean contains both soluble and insoluble fiber, which may have different extent of influence on the gut microbiome. Using a real food rather than a purified fiber such as pectin is more practical and more acceptable to families.
Primary Outcome Measure Information:
Title
Symptoms
Description
To assess the rate of continuation and symptoms/signs leading to discontinuation of fiber addition in SBS vs controls
Time Frame
3 weeks-6 months
Secondary Outcome Measure Information:
Title
Microbiome/Metabolome Changes
Description
To correlate changes in clinical status on fiber to microbiome/metabolome changes in SBS vs controls
Time Frame
3 weeks-6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Months
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Actively follows at CHOP outpatient clinics SBS arm specific: History of SBS diagnosis. History of short bowel syndrome based on surgical/imaging records. Has ileocecal resection (No ICV) and small bowel is in continuity with some portion of colon Control arm specific: No history of intestinal pathologies No or negligible amount (few bites of fiber-containing foods okay) of fiber in tube feeds or by mouth at baseline Less than 20% calories from oral food not containing fiber while the other 80% may be by enteral and/or parenteral feedings At least 20% calories from fiber-free formula taken orally or via tube Antibiotic use is allowed, however, should be on a stable regimen of antibiotics starting from 2 weeks prior to intervention until end of study or end of week 3 whichever is sooner. Instances of antibiotic use for brief courses (7-10 days) as long as sample collection is scheduled to be at least a week from the end date of antibiotics. Previous history of fiber introduction failure is acceptable as long as clinically stable at the time of recruitment Fiber supplementation is appropriate per primary physician If subject is unable to provide full set of samples, they will still be enrolled Exclusion Criteria: SBS Arm specific: No diagnosis of SBS. No history of ICV resection. Control Arm specific: has baseline intestinal diseases Small bowel and colon not in continuity (Ex: presence of ileostomy or jejunostomy) >5% changes in percentage of calories from PO, EN and/or PN during the intervention Addition/discontinuation/significant alteration to antibiotics regimen during study period Primary physician does not think fiber supplementation is appropriate clinically
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Wenjing Zong, MD
Phone
2674557884
Email
zongw@chop.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wenjing Zong, MD
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christina Bales, MD
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lindsey Albenberg, DO
Organizational Affiliation
Children's Hospital of Philadelphia
Official's Role
Study Director
Facility Information:
Facility Name
Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wenjing Zong, MD
Phone
267-455-7884
Email
zongw@chop.edu
First Name & Middle Initial & Last Name & Degree
Jackie Kirsch, BS
Phone
2155190747
Email
kirschj@chop.edu
First Name & Middle Initial & Last Name & Degree
Wenjing Zong, MD
First Name & Middle Initial & Last Name & Degree
Christina Bales, MD
First Name & Middle Initial & Last Name & Degree
Lindsey Albenberg, DO

12. IPD Sharing Statement

Learn more about this trial

Fiber Food Introduction in Pediatric Short Bowel Syndrome

We'll reach out to this number within 24 hrs